Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a specific reporting date of July 12, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions executed on July 11, 2019, on the London Stock Exchange (XLON). The transactions involved the acquisition of ordinary shares (ISIN: GB0009252882) at a price of £16.5223 per share.
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Dividend Re-investment | Ordinary Shares | 16.5223 | 1,249 shares |
Note: Total volume is the aggregate of individual transactions listed in the filing (29 + 5 + 702 + 514).
Material Changes
The filing does not report material changes to the company's business operations, financial position, or market conditions compared to prior periods. The only changes reported are the incremental increases in shareholdings for the specific individuals listed due to dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of routine share acquisitions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares resulting from the re-investment of dividends paid on July 11, 2019.
- Participants: The transactions involved Mrs. V A Whyte (Company Secretary), Mrs. S Jackson (SVP, Global Communications & CEO Office), Mr. I W Whyte (PCA of Mrs. V A Whyte), and Mrs. D Connor (PCA of Mr. R G Connor, President, Global Vaccines).
- Market Price: The shares were acquired at a uniform price of £16.5223.
- Scope: This document does not provide financial performance data; investors should refer to GSK's Form 20-F or quarterly earnings releases for revenue and profit metrics.